News | April 26, 2010

Pulmonary Arterial Hypertension Therapy Hits Market

A new formulation of Epoprostenol for Injection is stable at room temperature for up to 24 hours when diluted.

April 22, 2010 — An improved formulation of epoprostenol for the treatment of primary pulmonary arterial hypertension (PAH) and pulmonary hypertension is now commercially available.

Actelion Pharmaceuticals US, Inc., recently made the announcement regarding epoprostenol for injection, a therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe PAH, a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual..

Simultaneously, the company has launched the PROSPECT registry, a multicenter, observational, U.S. registry that will provide additional clinical experience on patients being treated with epoprostenol for Injection.

Unlike other epoprostenol formulations, epoprostenol for injection is stable at room temperature for up to 24 hours when diluted and put into the pump for administration, eliminating the need for ice packs.

Accredo Health Group Inc., a wholly owned subsidiary of Medco Health Solutions Inc., will serve as the sole specialty pharmacy provider of epoprostenol for injection.

"Patients with late-stage PAH are extremely ill and have little energy, so a therapy that is convenient could make a big difference in their daily lives," said Vallerie McLaughlin, M.D., professor and director of the pulmonary hypertension program at the University of Michigan. "In addition, the PROSPECT registry will be valuable in enhancing our understanding of patient response to epoprostenol for injection, and will help physicians provide the most appropriate care to patients."

Epoprostenol for injection is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in New York Heart Association Class III and Class IV patients who do not respond adequately to conventional therapy. Epoprostenol for injection can be reconstituted with either sterile water for injection or sodium chloride 0.9 percent injection, eliminating the need for drug-specific dilutions.

For more information: www.epoprostenol.com.

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Overlay Init